| 0 (0%) | 01-19 18:51 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.51 |
1-year : | 0.6 |
| Resists | First : | 0.43 |
Second : | 0.51 |
| Pivot price | 0.37 |
|||
| Supports | First : | 0.35 |
Second : | 0.31 |
| MAs | MA(5) : | 0.36 |
MA(20) : | 0.37 |
| MA(100) : | 0.37 |
MA(250) : | 0.47  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 37.7 |
D(3) : | 34.3 |
| RSI | RSI(14): 56.2 |
|||
| 52-week | High : | 0.98 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ VXRT ] has closed below upper band by 35.8%. Bollinger Bands are 11.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.36 - 0.36 | 0.36 - 0.36 |
| Low: | 0.33 - 0.34 | 0.34 - 0.34 |
| Close: | 0.36 - 0.36 | 0.36 - 0.36 |
Sun, 18 Jan 2026
The 3 Penny Stocks You Swore You’d Never Buy (But You’ll Check Anyway) - MarketBeat
Thu, 15 Jan 2026
Vaxart (VXRT) Advances Oral Vaccine with Promising Phase 1 Trial Results - GuruFocus
Tue, 13 Jan 2026
Vaxart’s Oral Vaccine Bet Hits A Funding Wall - Finimize
Thu, 25 Dec 2025
Vaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - Time to Sell? - MarketBeat
Fri, 14 Nov 2025
Vaxart, Precigen among biotech gainers after Q3 results - Seeking Alpha
Thu, 13 Nov 2025
Vaxart Inc (VXRT) Q3 2025 Earnings Call Highlights: Strategic Partnership and Revenue Surge ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 229 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 21,170 (K) |
| Shares Short P.Month | 14,350 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.7 |
| PEG Ratio | 0 |
| Price to Book value | 1.5 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 12.18 |
| Forward Dividend | 0 |
| Dividend Yield | 3125.6% |
| Dividend Pay Date | 2024-12-19 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|